Search the Newsreel

Wall Street Analysts Are Bullish on Top Healthcare Picks

This article highlights bullish sentiments from Wall Street analysts on three healthcare companies: Prelude Therapeutics (PRLD), Candel Therapeutics (CADL), and NeuroPace (NPCE). H.C. Wainwright analysts reiterated Buy ratings for all three, setting price targets of $8.00, $23.00, and $20.00 respectively. The article provides details …

Kestrel Group Ltd. (KG) Q3 2024 Earnings: Loss Per Share of $0.16 as Shares Dip 0.35% - Earnings Per Share

Bank Ireland Group PLC (BKRIY) Q2 FY2026 earnings call transcript

Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?

Kestrel Group Ltd. (KG) Q3 2024 Earnings: Loss Per Share of $0.16 as Shares Dip 0.35% - Management Guidance Update

Perella Weinberg Partners Q2 Earnings Call Highlights

Perella Weinberg Partners Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …

Perella Weinberg Partners (NASDAQ:PWP) Shares Gap Up Following Better-Than-Expected Earnings

Perella Weinberg Partners (PWP) Earnings Date and Reports 2026

Perella Weinberg (NASDAQ:PWP) Delivers Impressive Q2 CY2026

Perella Weinberg (NASDAQ:PWP) Delivers Impressive Q2 CY2026 Financial advisory firm Perella Weinberg Partners (NASDAQ:PWP) reported Q2 CY2026 results beating Wall Street's revenue expectations , but sales were flat year on year at $156.5 million. Its non-GAAP profit of $0.20 per share was significantly above …

Why Perella Weinberg (PWP) Stock Is Trading Up Today

Why Perella Weinberg (PWP) Stock Is Trading Up Today What Happened? Shares of financial advisory firm Perella Weinberg Partners (NASDAQ:PWP) jumped 17.5% in the morning session after the company reported second-quarter results that crushed Wall Street's profit expectations. The company announced adjusted earnings per …

Perella Weinberg Partners (NASDAQ:PWP) Issues Quarterly Earnings Results

What Has Changed for Aurelia Metals (ASX:AMI)?

Bank of Ireland Group PLC (BIRG.SG) Q2 FY2026 earnings call transcript

Earnings call transcript: Bank of Ireland lifts 2026 outlook after strong H1

Franklin Wireless Corp (FKWL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Franklin Wireless Corp (FKWL), noting its current valuation score of 9.03 within the Communications & Networking industry. It highlights the company's negative P/E ratio of -37.55 and indicates that key valuation metrics such as P/E, P/B, P/S, …

Franklin Wireless Corp (FKWL) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Franklin Wireless Corp (FKWL), detailing its current price momentum score as 2.96, ranking it low within the Communications & Networking industry. It highlights the stock's trading range between a resistance level of $2.49 and a support level …

Is Relay Therapeutics (RLAY) Turning Zovegalisib Updates Into a Credibility Test for Its Pipeline Strategy?

Relay Therapeutics is nearing its Q2 2026 earnings report, with significant investor attention on updates for its lead asset, zovegalisib, and other pipeline programs. Analysts are increasingly optimistic, anticipating strong earnings and progress in oncology and genetic disease trials. The company recently completed a …

Relay Therapeutics to report Q2 2026 results on Aug 6

Relay Therapeutics, Inc. (NASDAQ: RLAY) will announce its second-quarter 2026 financial results and corporate highlights after U.S. financial markets close on August 6, 2026. The clinical-stage precision medicine company focuses on developing therapies for cancer and genetic diseases, with its lead asset, zovegalisib, currently …

Reliance (RS) Could Be 4% Overvalued As Strong Q2 Earnings Draw Fresh Attention

Press Release: Reliance Global Group Reports Second Quarter 2026 Results and Accelerates AI-Driven Transformation

Reliance Global Group (NASDAQ: RELI) announced its financial results for the second quarter of 2026, highlighting significant revenue growth and a reduced net loss. The company is actively integrating AI into its operations to enhance efficiency and client satisfaction, particularly through its Reliz Insurance …

Reliance Global Q2 net loss narrows 26% to $2.0M on cost cuts

Reliance Global Group (NASDAQ: EZRA) reported a 26% reduction in its Q2 2026 net loss, narrowing it to $2.0 million from $2.7 million in the prior year, primarily due to disciplined cost management and lower non-cash share-based compensation. While commission income declined due to …

Earnings call transcript: Reliance Global cuts loss in Q2 2026 as AI push lifts hopes

Reliance Global Group (EZRA) narrowed its Q2 2026 net loss by 26% to $2.0 million, down from $2.7 million a year prior, driven by significant expense reductions and a strategic portfolio realignment. The insurance and technology company highlighted its advancements in AI, stating the …

Reliance Global Group, Inc. Q2 2026: Revenue $2.11M, EPS $(3.26) — 10-Q Summary

Reliance Global Group, Inc. reported its Q2 2026 financial results, showing revenue of $2.11M and a diluted loss per share of $(3.26), an improvement from the prior year. The company's revenue decreased year-over-year due to divestitures, but operating expenses also fell, contributing to improved …

Relay Therapeutics (RLAY) CFO sells 1,459 shares to cover taxes

Relay Therapeutics' CFO, Thomas Catinazzo, sold 1,459 shares of common stock at $18.61 per share on July 28, 2026. This transaction was solely to cover income tax withholding obligations from the vesting of 3,269 Restricted Stock Units (RSUs) and was conducted without his discretion, …

Relay Therapeutics to report Q2 results after markets close

Relay Therapeutics is scheduled to release its second-quarter 2026 financial results and provide a corporate update on August 6, 2026, after the U.S. market closes. This information was originally published by Relay Therapeutics Inc. via GlobeNewswire. The news brief was generated by Public Technologies …

Relay Therapeutics, Inc. (RLAY) insider sale covers RSU tax

Relay Therapeutics, Inc. President of R&D, Donald A. Bergstrom, sold 2,237 shares of common stock on July 28, 2026, at $18.61 per share. This sale was explicitly to cover income tax withholding obligations from the vesting of 5,012 Restricted Stock Units (RSUs) on July …

Relay Therapeutics schedules its next financial update for Aug. 6

Relay Therapeutics (Nasdaq: RLAY) will report its second quarter 2026 financial results and corporate highlights after the U.S. market closes on Thursday, August 6, 2026. This announcement from the clinical-stage small molecule precision medicine company provides investors and analysts with the upcoming earnings date. …

Relay Therapeutics (RLAY) officer has 748 shares sold to satisfy RSU tax

Relay Therapeutics' Chief Corporate Development Officer, Peter Rahmer, sold 748 shares of common stock at $18.61 per share on July 28, 2026. This sale was non-discretionary and executed to cover income tax withholding obligations from the vesting of 3,051 Restricted Stock Units (RSUs). After …

Reliance Global Begins Deploying AI for Insurance Workflow Automation

Reliance Global Group (NASDAQ: EZRA) reported its Q2 2026 financial results, which included a net loss reduction and a focus on accelerating its proprietary AI platform for insurance operations. The company launched an AI agent for secure browser automation and is deploying AI capabilities …

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the …

PRLD|Prelude Therapeutics Inc|Price:4.520|Chg%:+0.130

This article provides a comprehensive stock analysis of Prelude Therapeutics Inc (PRLD) by TradingKey, highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. It notes high institutional ownership and multiple "Buy" ratings from analysts, with a …

Kardan Real Estate Enterprise & Development Ltd. Revenue Breakdown – TASE:KARE

Prelude Therapeutics Inc (PRLD) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Prelude Therapeutics Inc (PRLD), assigning it a score of 6.29 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is deemed stable, but its operating efficiency is low. Key financial dimensions like …

RELX Group Number of Employees 2026 | Employee Count & Headcount Data

RELX Group Plc had approximately 12,602 employees worldwide as of March 2026, representing a 9.7% growth from 2023. The company is actively hiring, with 1,558 active job postings in 2026, a 47.0% increase from 2025. Its workforce is concentrated in the United States, United …

M N C Wireless Berhad Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026

The Technical Signals Behind (GIII) That Institutions Follow

This article analyzes G-III Apparel Group Ltd. (NASDAQ: GIII) through the lens of institutional trading signals generated by AI models. It highlights strong sentiment supporting an overweight bias, outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/target/stop loss levels, and provides a …